Direct Oral Anticoagulants versus Warfarin in Patients with Bioprosthetic Heart Valves and Atrial Fibrillation: A Systematic Review and Meta-analysis
Chinese Journal of Cancer Prevention and Treatment · 25.07.2026 · 33 (7) · 49-55
DOI: 10.61336/cjpt/26-7-5 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Chinese Journal of Cancer Prevention and Treatment, online erschienen am 25.07.2026.
Abstract (Originalsprache)
Patients with prosthetic heart valves require long-term anticoagulation, and many have concomitant atrial fibrillation (AF). Warfarin has been the standard of care, but direct oral anticoagulants (DOACs) offer predictable pharmacokinetics, fixed dosing and freedom from routine monitoring. Their comparative performance in prosthetic valve populations remains uncertain.
Objectives
To compare the efficacy and safety of DOACs versus warfarin for long-term anticoagulation in adults with mechanical or bioprosthetic heart valves.
Methods
This systematic review and meta-analysis followed PRISMA 2020 and was registered in PROSPERO (CRD420251232927). PubMed, Scopus and ClinicalTrials.gov were searched to 30 October 2025. Eligible studies compared a DOAC with warfarin in adults (≥18 years) with mechanical or bioprosthetic valves receiving chronic anticoagulation. Risk of bias was assessed with RoB 2 and ROBINS-I, and certainty with GRADE. Dichotomous outcomes were pooled as odds ratios (ORs) with 95% confidence intervals (CIs) using random-effects meta-analysis (Mantel–Haenszel); heterogeneity was quantified with Cochran's Q and I².
Results
Six studies (27,261 patients) were included; all enrolled patients with bioprosthetic valves and AF, and no mechanical valve study was eligible. Three observational studies (810 DOAC, 1,383 warfarin) provided extractable event data. No significant difference was found for thromboembolic stroke (OR 0.90, 95% CI 0.45–1.77; I² = 30%), major bleeding (OR 0.93, 95% CI 0.69–1.25; I² = 0%), all-cause mortality (OR 1.24, 95% CI 0.91–1.70; I² = 0%), minor bleeding (OR 1.12, 95% CI 0.79–1.58; I² = 0%) or the composite endpoint (OR 1.08, 95% CI 0.72–1.62; I² = 64%). All non-randomised studies were at serious risk of bias, and certainty was very low for every outcome.
Conclusions
In patients with bioprosthetic valves and AF, DOACs and warfarin showed comparable rates of stroke, bleeding and death, supporting DOACs as a reasonable option in selected patients. The evidence is of very low certainty and largely observational. No eligible evidence exists for mechanical valves, in which DOACs remain contraindicated.
Zitieren
APA
(2026). Direct Oral Anticoagulants versus Warfarin in Patients with Bioprosthetic Heart Valves and Atrial Fibrillation: A Systematic Review and Meta-analysis. Chinese Journal of Cancer Prevention and Treatment, 33(7), 49-55. https://doi.org/10.61336/cjpt/26-7-5
Vancouver
Direct Oral Anticoagulants versus Warfarin in Patients with Bioprosthetic Heart Valves and Atrial Fibrillation: A Systematic Review and Meta-analysis. Chinese Journal of Cancer Prevention and Treatment. 2026;33(7):49-55. doi:10.61336/cjpt/26-7-5
BibTeX
@article{euvimed2026,
title = {Direct Oral Anticoagulants versus Warfarin in Patients with Bioprosthetic Heart Valves and Atrial Fibrillation: A Systematic Review and Meta-analysis},
journal = {Chinese Journal of Cancer Prevention and Treatment},
year = {2026},
volume = {33},
number = {7},
pages = {49--55},
doi = {10.61336/cjpt/26-7-5}
}
EUVIMED